Shilpa Medicare Limited’s 100% subsidiary, Shilpa Pharma Lifesciences Limited has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Octreotide.

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors.

Octreotide is the second peptide molecule in Shilpa’s peptide portfolio. The CEP showcases our expertise and commitment to quality-oriented development and commercial production, which meets the expectations of global quality standards.